Previous Study: TRIO 014
Next Study: TRIO 016

Studies & Results

TRIO 015

A multicenter open label Phase II study of the efficacy and safety of AMG 479, a fully human monoclonal antibody against insulin-like growth factor Type 1 receptor (IGF-1R) as second line therapy in patients with recurrent platinum-sensitive ovarian cancer

View FDA Study View EU Study

Presentations

ASCO Annual Meeting, 2013

Ray-Coquard I, Haluska P, O’Reilly S, et al

A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org